Triple Receptor Agonists Explained: GIP, GLP-1 and Glucagon in One Molecule

What a triple receptor agonist is, why the glucagon arm was the hard part, and what the published preclinical and clinical literature actually reports.

By Published Updated

A triple receptor agonist is a single peptide that binds and activates three different receptors. In the metabolic literature the phrase almost always means one specific combination: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor — GIPR, GLP-1R and GCGR.

This article sets out what that design is, where it came from, how such a molecule is built, and what the published research reports at each level of evidence. It describes research. It is not a comparison of products, it names no preferred compound, and it contains no guidance of any kind on handling any material.

Why three receptors rather than one

The single-receptor era of this field was defined by the glucagon-like peptide-1 receptor. Native GLP-1 is an incretin hormone: released from enteroendocrine cells of the gut after a meal, it acts at a class B1 G protein-coupled receptor on pancreatic islet cells to modulate glucose-dependent insulin secretion, and at receptors in the central nervous system involved in regulating food intake [1, 5]. Its pharmacology has been reviewed at length, and the mechanism is among the best characterised in endocrinology [4, 8].

The problem native GLP-1 presents is not potency but duration: dipeptidyl peptidase-4 cleaves it within minutes, and what survives is cleared renally almost as quickly. The whole first generation of GLP-1 receptor analogues is a set of solutions to that problem rather than to any receptor-level question [6].

Once duration was solved, the remaining question changed shape. Adding more of the same receptor activity runs into the tolerability limits of that receptor — the gastrointestinal events that dominate the adverse-event tables of every trial in this family. Engaging a different receptor, in a different tissue, is a different kind of addition. That is the reasoning behind multi-agonism, and the tri-agonist is its furthest published expression in this receptor family.

The three receptors, and what each contributes

All three targets are class B1, or secretin-like, G protein-coupled receptors, and all three couple through Gs to raise intracellular cyclic AMP [13]. They are not, however, interchangeable, because they sit in different tissues and drive different processes.

The GLP-1 receptor was cloned from pancreatic beta cells in 1992 [1]. Its physiology comprises glucose-dependent insulin secretion, suppression of glucagon secretion, slowing of gastric emptying, and central effects on food intake [5]. This is the arm every compound in the family shares.

The GIP receptor was cloned in 1993 and shown to be distributed widely across peripheral organs and the brain [3]. GIP is the other incretin hormone. Its role in metabolic pharmacology has been argued about for longer than any of these compounds have existed, and the argument is not settled: both agonism and antagonism at this receptor have plausible mechanistic rationales, both have been pursued clinically, and the two cases have been set out in parallel review articles [23, 22].

The glucagon receptor was cloned in 1993 from rat and characterised for its signalling properties [2]. Its principal tissue is liver, and glucagon receptor signalling raises whole-body metabolic rate. It also raises blood glucose when unopposed — which is why glucagon agonism was for decades treated as something to be avoided in diabetes research rather than pursued [15]. The relationship between the liver and the pancreatic alpha cell that produces glucagon has since been re-examined as a feedback loop in its own right [10], and the concept of glucagon resistance has been reviewed as a distinct phenomenon [11].

The tri-agonist premise, stated in its discovery literature, is that the two incretin arms hold glucose in check while the glucagon arm contributes a separate route to metabolic change — so that the glycaemic liability of glucagon agonism is offset inside the same molecule rather than by a second drug [13].

How such a molecule is actually built

A tri-agonist is not three peptides joined together. It is one backbone whose sequence has been engineered so that a single chain is recognised by three related receptors.

That is possible because the three hormones involved — GIP, GLP-1 and glucagon — belong to the same peptide superfamily and share substantial sequence homology, so their receptors have overlapping recognition requirements. The engineering problem is to find a chain that satisfies all three at once, and then to tune how strongly it satisfies each.

The relative potencies are the design parameter. In a multi-agonist the balance between receptor activities distinguishes one molecule from another far more than the backbone does. Retatrutide is reported as balanced between the glucagon and GLP-1 receptors with relatively greater activity at the GIP receptor [13]; the dual agonist tirzepatide is reported as imbalanced toward GIPR relative to GLP-1R [9]. Those are characterisations of cell-based assay behaviour.

Two modifications are near-universal in this family. The first is stabilisation against dipeptidyl peptidase-4 at the positions most exposed to it, usually by substituting residues that have no single-letter representation in standard sequence notation. The second is acylation: a fatty acid or fatty diacid attached to a lysine side chain through a linker, which binds the peptide reversibly to serum albumin. Albumin binding protects against both proteolysis and glomerular filtration and is what converts a half-life of minutes into one of days — approximately six days for retatrutide in early clinical study [13, 14].

A consequence worth noting: the published single-letter sequence of such a molecule is rarely the complete covalent structure. Registers frequently record the backbone only, so the mass calculated from the letters and the mass of the finished molecule can differ by hundreds of daltons, and that difference is the modification chemistry rather than a discrepancy.

Where the concept came from

Animal research

The tri-agonist idea is older than any compound now in late-stage development, and it was established in rodents.

A rationally designed monomeric peptide triagonist at GIPR, GLP-1R and GCGR was reported in 2015 and characterised in rodent models of obesity and diabetes [7]. That paper established that a single chain could engage all three receptors and that the combination behaved differently from its parts in an animal.

Later work compared successive generations of GLP-1/GIP/glucagon triple agonists in obese mice, examining how the balance between the three activities changes what the molecule does [12].

The most informative rodent result for the specific premise of the design came with retatrutide's discovery paper. In diet-induced obese mice, body-mass reduction separated into two contributions: a reduction in calorie intake attributable to the GIP and GLP-1 receptor arms, and an increase in whole-body metabolic rate attributable to the glucagon receptor arm, added on top [13]. That decomposition is the mechanistic claim the whole programme rests on, and it was demonstrated in mice years before any human phase 3 result existed.

Diet-induced obesity models in rodents are a standard preclinical tool and a poor predictor of human results in this field specifically. Findings described in this section were observed in animals, and nothing in them establishes anything about humans.

What the cell-based pharmacology shows

In vitro research

The in vitro layer is where a multi-agonist is defined, because "triple agonist" is a statement about activity at three cloned receptors in cell-based assays.

Retatrutide's discovery characterisation reports balanced activity at the glucagon and GLP-1 receptors with relatively greater activity at the GIP receptor, alongside the structural features responsible for its duration: a backbone stabilised against dipeptidyl peptidase-4, and a fatty diacid attached to a lysine side chain through a hydrophilic linker [13]. The dual agonist tirzepatide was characterised in the same way at two receptors, with activity at GIPR comparable to native GIP and weaker relative activity at GLP-1R than native GLP-1 [9].

Three cautions apply to any comparison of these numbers.

First, they come from different papers, different assay formats and different reference standards, so potencies reported for two compounds at the same receptor are not interchangeable.

Second, potency at a cloned receptor in a transfected cell line does not predict a proportional effect in tissue. The receptors in question sit in different organs at different densities, and a balanced profile in a dish is not a balanced profile in a body.

Third, the albumin binding that defines the pharmacokinetics of every compound in this family is absent from the assay entirely.

What has been reported in human trials

Human clinical research

Results from pharmaceutical clinical trials describe the investigational material and populations used in those studies and should not be interpreted as establishing the effects of research-grade materials offered for laboratory use.

The clinical record for triple receptor agonism is at present essentially the record of one compound, retatrutide, and it is younger than the records of the single- and dual-receptor compounds beside it.

Phase 1b. 72 adults with type 2 diabetes over 12 weeks. Pharmacokinetics were proportional to the amount administered, with a plasma half-life of approximately six days; placebo-adjusted glycated haemoglobin fell by 1.2% to 1.6% in the three highest groups. 29 of 72 participants discontinued prematurely [14].

Phase 2 in obesity. 338 adults randomised to once-weekly subcutaneous administration for 48 weeks. Least-squares mean change in body weight at 48 weeks was −8.7%, −17.1%, −22.8% and −24.2% across the groups against −2.1% for placebo. Adverse events were most commonly gastrointestinal, graded with the amount administered, mostly mild to moderate, and partially mitigated by a lower starting amount [16].

Phase 2 in type 2 diabetes. 281 adults, placebo-controlled and active-controlled against dulaglutide 1.5 mg. Glycated haemoglobin change at 24 weeks ranged from −0.43% to −2.02% against −0.01% for placebo and −1.41% for dulaglutide [17].

Phase 2a in liver disease. 98 participants with metabolic dysfunction-associated steatotic liver disease and at least 10% liver fat. Mean relative change in liver fat at 24 weeks was −42.9% to −82.4% across groups against +0.3% for placebo, measured by imaging rather than histology and with no measure of fibrosis [20].

Phase 3. TRANSCEND-T2D-1 randomised 537 adults with type 2 diabetes and reported mean glycated haemoglobin change of −1.69% to −1.94% against −0.81% for placebo at 40 weeks, with predominantly mild-to-moderate gastrointestinal events and discontinuations for adverse events of 2–5% against 0% for placebo [26]. The TRIUMPH registrational trials in obesity, obstructive sleep apnoea and osteoarthritis of the knee were designed as a linked set and have completed their primary phases [25].

What this record does not contain. No outcome trial. No trial counting deaths, myocardial infarctions, strokes or kidney failure has reported for any triple receptor agonist. Every endpoint above is a laboratory measure, an imaging measure or an anthropometric measure. And no head-to-head trial of a triple agonist against a dual agonist has been published, so the gap between the two classes has never been measured directly — published systematic analyses of approved incretin mimetics are explicit that indirect comparison across separate placebo-controlled trials rests on assumptions that head-to-head randomisation does not require [21].

Regulatory position. No triple receptor agonist is approved for any indication, in the United States or elsewhere. Approval in the United States attaches to a specific compound and a specific indication, and approvals held by single- and dual-receptor compounds in this family confer nothing on the triple agonists.

The dual agonists that sit alongside

Human clinical research

Results from pharmaceutical clinical trials describe the investigational material and populations used in those studies and should not be interpreted as establishing the effects of research-grade materials offered for laboratory use.

Triple agonism is one branch of a wider multi-agonist programme, and two of the other branches are useful for locating it.

GIP plus GLP-1. Tirzepatide is the dual agonist at those two receptors and the most extensively tested multi-agonist in the family, with a completed phase 3 programme and a cardiovascular outcome trial against an active comparator [9].

Glucagon plus GLP-1, without GIP. This is the branch that isolates the glucagon question. Survodutide, a glucagon and GLP-1 receptor dual agonist, reported a phase 2 amount-finding trial in obesity [19], a phase 2 trial in type 2 diabetes that included open-label semaglutide as a comparator [18], and a phase 3 trial in adults with obesity [27]. Mazdutide, another glucagon and GLP-1 receptor dual agonist, reported a phase 3 trial in Chinese adults with obesity or overweight [24].

That branch matters for reading the tri-agonist literature, because it tests glucagon receptor agonism without the GIP arm. What it cannot do is isolate the GIP contribution within a tri-agonist, which would require a comparison that has not been run.

What is still unsettled

Three questions remain open in the published literature, and the honest position is that none of them has been answered.

Whether the third arm adds what the design predicts, in humans. The decomposition of effect into incretin and glucagon contributions was demonstrated in mice [13]. No human study has separated those contributions, and no trial has compared a tri-agonist with a dual agonist directly.

What the optimal balance between the three activities is. The relative potencies are tunable, successive generations of molecules have been built with different balances [12], and no clinical comparison of different balances exists.

Whether the surrogate endpoints translate. Every published tri-agonist endpoint is a surrogate. Whether changes in glycated haemoglobin, body weight or hepatic fat fraction under a triple agonist translate into the clinical outcomes that single-receptor compounds in this family have demonstrated is an empirical question, and the trials that would answer it have not reported.

All of the research described in this article is research into pharmaceutical product candidates, conducted by their sponsors under registered protocols, using investigational material manufactured to a regulatory standard and administered under clinical supervision in defined populations. None of it is research into, or evidence about, research-grade material supplied for laboratory use.

Frequently Asked Questions

What is a triple receptor agonist?
A single peptide that binds and activates three receptors. In the metabolic literature the phrase means one specific combination: the GIP receptor, the GLP-1 receptor and the glucagon receptor, all class B1 G protein-coupled receptors that couple through Gs to raise intracellular cyclic AMP [13]. It is one molecule, not three joined together.
Why is the glucagon receptor the difficult one?
Because it acts in the opposite direction on blood glucose from the other two. Glucagon receptor signalling, principally in liver, raises whole-body metabolic rate but also raises blood glucose when unopposed, which is why glucagon agonism was avoided in diabetes research for decades [2, 15]. The tri-agonist premise is that the two incretin arms offset that liability within the same molecule [13].
Which compounds are triple receptor agonists?
Retatrutide is the compound with the most advanced published clinical record for this receptor combination [13, 26]. Rodent work on the concept predates it, including a monomeric triagonist reported in 2015 [7] and later generations characterised in obese mice [12]. No triple receptor agonist is approved anywhere.
How is a triple agonist different from a dual agonist?
By one receptor. Tirzepatide engages GIPR and GLP-1R [9]; a tri-agonist adds GCGR [13]. There is also a branch of dual agonists that combines glucagon and GLP-1 without GIP, including survodutide and mazdutide [19, 24]. No trial has compared a triple agonist directly with a dual agonist.
Has a triple agonist been compared head-to-head with anything?
Against dulaglutide 1.5 mg, in one phase 2 trial in type 2 diabetes [17]. Every other published trial has been placebo-controlled [16, 26]. There is no head-to-head trial against a dual agonist or against a single-receptor GLP-1 analogue.
Are triple receptor agonists FDA approved?
No. None is approved for any indication in the United States or elsewhere. Approval attaches to a specific compound and a specific indication, so approvals held by other compounds in this receptor family confer nothing on the triple agonists.
What does the published human evidence actually measure?
Surrogate endpoints. Glycated haemoglobin, body weight, hepatic fat fraction by imaging, and adverse-event rates [14, 16, 20, 26]. No outcome trial counting deaths, myocardial infarctions, strokes or kidney failure has reported for any triple receptor agonist.

References

  1. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1 Proceedings of the National Academy of Sciences of the United States of America; 1992. PMID 1326760 doi:10.1073/pnas.89.18.8641
  2. Expression cloning and signaling properties of the rat glucagon receptor Science; 1993. PMID 8384375 doi:10.1126/science.8384375
  3. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain Endocrinology; 1993. PMID 8243312 doi:10.1210/endo.133.6.8243312
  4. Biology of incretins: GLP-1 and GIP Gastroenterology; 2007. PMID 17498508 doi:10.1053/j.gastro.2007.03.054
  5. The physiology of glucagon-like peptide 1 Physiological Reviews; 2007. PMID 17928588 doi:10.1152/physrev.00034.2006
  6. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide Journal of Medicinal Chemistry; 2015. PMID 26308095 doi:10.1021/acs.jmedchem.5b00726
  7. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents Nature Medicine; 2015. PMID 25485909 doi:10.1038/nm.3761
  8. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 Cell Metabolism; 2018. PMID 29617641 doi:10.1016/j.cmet.2018.03.001
  9. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept Molecular Metabolism; 2018. PMID 30473097 doi:10.1016/j.molmet.2018.09.009
  10. The Liver-α-Cell Axis and Type 2 Diabetes Endocrine Reviews; 2019. PMID 30920583 doi:10.1210/er.2018-00251
  11. Glucagon Receptor Signaling and Glucagon Resistance International Journal of Molecular Sciences; 2019. PMID 31284506 doi:10.3390/ijms20133314
  12. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice Molecular Metabolism; 2022. PMID 35809773 doi:10.1016/j.molmet.2022.101533
  13. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Cell Metabolism; 2022. PMID 35985340 doi:10.1016/j.cmet.2022.07.013
  14. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial The Lancet; 2022. PMID 36354040 doi:10.1016/S0140-6736(22)02033-5
  15. 100 years of glucagon and 100 more Diabetologia; 2023. PMID 37367959 doi:10.1007/s00125-023-05947-y
  16. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial The New England Journal of Medicine; 2023. PMID 37366315 doi:10.1056/NEJMoa2301972
  17. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA The Lancet; 2023. PMID 37385280 doi:10.1016/S0140-6736(23)01053-X
  18. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial Diabetologia; 2024. PMID 38095657 doi:10.1007/s00125-023-06053-9
  19. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial The Lancet Diabetes & Endocrinology; 2024. PMID 38330987 doi:10.1016/S2213-8587(23)00356-X
  20. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Nature Medicine; 2024. PMID 38858523 doi:10.1038/s41591-024-03018-2
  21. Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials Diabetes, Obesity and Metabolism; 2025. PMID 40212008 doi:10.1111/dom.16398
  22. GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale Diabetes; 2025. PMID 40521869 doi:10.2337/dbi24-0027
  23. A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity Diabetes; 2025. PMID 40521890 doi:10.2337/dbi24-0026
  24. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight The New England Journal of Medicine; 2025. PMID 40421736 doi:10.1056/NEJMoa2411528
  25. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials Diabetes, Obesity and Metabolism; 2026. PMID 41090431 doi:10.1111/dom.70209
  26. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial The Lancet; 2026. PMID 42250575 doi:10.1016/S0140-6736(26)00967-0
  27. Survodutide Once Weekly for the Treatment of Adults with Obesity The New England Journal of Medicine; 2026. PMID 42253238 doi:10.1056/NEJMoa2600751

Every identifier above is resolved against PubMed, Crossref or ClinicalTrials.gov at build time, and the title returned by the register is compared with the title stored here. A page does not publish if a reference fails to resolve.

Research-Use Information

For in vitro research use only. This material is a laboratory reagent. It is not a drug, food, dietary supplement, or cosmetic and is not for human or veterinary use, including ingestion, injection, or any other administration. No information on this page describes or implies any effect in humans or animals. Sold only to researchers under our Terms of Sale.